TW202310874A - B7-h3抗體的藥物組合物及其用途 - Google Patents

B7-h3抗體的藥物組合物及其用途 Download PDF

Info

Publication number
TW202310874A
TW202310874A TW111126185A TW111126185A TW202310874A TW 202310874 A TW202310874 A TW 202310874A TW 111126185 A TW111126185 A TW 111126185A TW 111126185 A TW111126185 A TW 111126185A TW 202310874 A TW202310874 A TW 202310874A
Authority
TW
Taiwan
Prior art keywords
cancer
enoblituzumab
pharmaceutical composition
composition
container
Prior art date
Application number
TW111126185A
Other languages
English (en)
Chinese (zh)
Inventor
周岩
克里斯南 山帕斯庫瑪
史蒂芬詹姆士 柏克
王曉彥
Original Assignee
美商宏觀基因股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商宏觀基因股份有限公司 filed Critical 美商宏觀基因股份有限公司
Publication of TW202310874A publication Critical patent/TW202310874A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW111126185A 2021-07-16 2022-07-12 B7-h3抗體的藥物組合物及其用途 TW202310874A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163222750P 2021-07-16 2021-07-16
US63/222,750 2021-07-16

Publications (1)

Publication Number Publication Date
TW202310874A true TW202310874A (zh) 2023-03-16

Family

ID=84920541

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111126185A TW202310874A (zh) 2021-07-16 2022-07-12 B7-h3抗體的藥物組合物及其用途

Country Status (11)

Country Link
US (1) US20240336687A1 (https=)
EP (1) EP4370155A4 (https=)
JP (1) JP2024526773A (https=)
KR (1) KR20240038005A (https=)
CN (1) CN117715657A (https=)
AU (1) AU2022310668A1 (https=)
CA (1) CA3224118A1 (https=)
IL (1) IL310187A (https=)
MX (1) MX2024000690A (https=)
TW (1) TW202310874A (https=)
WO (1) WO2023288173A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2019246312A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
BR112022019073A2 (pt) * 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma

Also Published As

Publication number Publication date
CA3224118A1 (en) 2023-01-19
AU2022310668A1 (en) 2024-01-18
IL310187A (en) 2024-03-01
MX2024000690A (es) 2024-02-07
WO2023288173A1 (en) 2023-01-19
EP4370155A4 (en) 2025-06-11
JP2024526773A (ja) 2024-07-19
CN117715657A (zh) 2024-03-15
KR20240038005A (ko) 2024-03-22
US20240336687A1 (en) 2024-10-10
EP4370155A1 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
JP5513380B2 (ja) 肝細胞増殖因子に対する特異的結合剤の組成物
CA2885862A1 (en) Stable, low viscosity antibody formulation
ES2668900T3 (es) Formulaciones estabilizadas que contienen anticuerpos anti-Dll4
KR20210114989A (ko) 치료 항체 제제
US11958906B2 (en) Pharmaceutical compositions of mosunetuzumab and methods of use
TW202310874A (zh) B7-h3抗體的藥物組合物及其用途
CN119997972A (zh) 抗cd20抗体的药物组合物及其用途
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
US12364756B2 (en) Pharmaceutical compositions of a PD-1 antibody and use of the same
US20230140384A1 (en) Antibodies to cd40 with enhanced agonist activity
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
HK40112469A (zh) Pd-1抗体的药物组合物及其用途
TW202237185A (zh) Her2/neu抗體的藥物組合物及其用途
RU2824627C2 (ru) Фармацевтическая композиция анти-cd20 антитела и ее применение
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
CN116916952A (zh) HER2/neu抗体的药物组合物及其用途
WO2025140467A1 (zh) 稳定的高浓度抗pd-1抗体药物制剂
HK40102521A (zh) Her2/neu抗体的药物组合物及其用途
EA050933B1 (ru) Фармацевтические композиции антитела к pd-1 и применение указанной композиции
KR20230026407A (ko) 액티빈 a 항체 제형 및 이의 사용 방법
TW202128220A (zh) 穩定液體組合物、其製備方法及含有其之調配物
EA052238B1 (ru) Фармацевтическая композиция анти-cd20 антитела и ее применение
BR122025004506A2 (pt) Composições farmacêuticas compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo, método de preparação e usos das mesmas, bem como kit